Meeting
2018 ASCO Annual Meeting
A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.
Authors
Roisin Eilish O'Cearbhaill
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
Roisin Eilish O'Cearbhaill , Sacha Gnjatic , Carol Aghajanian , Alexia Iasonos , Jason A. Konner , Nicolle Losada , Debra Sarasohn , Teresa Rasalan , William P. Tew , Dmitriy Zamarin , Phillip Wong , Paul Sabbatini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02737787
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5553)
DOI
10.1200/JCO.2018.36.15_suppl.5553
Abstract #
5553
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Mark N. Stein
Poster
2022 ASCO Annual Meeting
A first-in-human, phase I, open-label study of a novel cancer vaccine labvax 3(22)-23 and adjuvant GM-CSF in patients with advanced stage adenocarcinomas.
First Author: Weijie Ma
Poster
2020 ASCO Virtual Scientific Program
GEN-009, a neoantigen vaccine containing ATLAS selected neoantigens, to generate broad sustained immunity against immunogenic tumor mutations and avoid inhibitory peptides.
First Author: Roger B. Cohen
Poster
2019 ASCO Annual Meeting
A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses.
First Author: Roger B. Cohen